Sovaldi wins round two in the battle to be the best-selling drug

25-07-2014 WSJ Pharmalot BlogComments (0)

Gilead SciencesSovaldi

In the fight to become the year's top-selling drug, the current champ - the Humira arthritis treatment - has gotten knocked down. Sovaldi, the pricey hepatitis C drug sold by Gilead Sciences, surpassed Humira in sales in the second quarter.

Read more on WSJ Pharmalot Blog

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top